It uses a machine learning algorithm to compute a risk score for distant recurrence over a timeline of five years with the inputs from IHC gradings of five biomarkers (CD44, ABCC4, ABCC11, N-Cadherin, and pan-Cadherin) along with three clinical parameters (node status, tumor size, and tumor grade) [11-13]. This evidence concerns the gene ADA2 and neoplasm.